NAD disapproves of irrelevant images
This article was originally published in The Tan Sheet
Brain Research Labs should discontinue use of before-and-after brain scans to demonstrate the efficacy of its cognitive supplement Procera AVH because the images demonstrate an ingredient's impact on the brain and not the supplement's impact, according to the National Advertising Division. NAD argues the images are irrelevant and do not accurately depict brain function or how the supplement works. Also, the images imply the product works immediately, which evidence does not support, the Council of Better Business Bureaus unit says. NAD also recommends the advertiser discontinue claims of "double proof of efficacy," because substantiation comes from one study. That study, however, adequately supports claims that use of Procera will "energize the brain, uplift mood, improve memory and sharpen the mind," and claims that Procera improves concentration and reduces hostility. Brain Research Labs voluntarily discontinued claims Procera improves IQ and reduces anxiety, according to NAD's Sept. 14 release
You may also be interested in...
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.
The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.